Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01690468 · ClinicalTrials.gov registry record · Phase 1
PTX-200 and Carboplatin in Ovarian Cancer
A Phase 1 study, sponsored by Prescient Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01690468 is a Phase 1 study that was terminated before completion, run by Prescient Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT01690468, a Phase 1 study, was terminated before completion, sponsored by Prescient Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine if Triciribine (TCN) and carboplatin are safe and tolerable when given together, and to determine if this combination of drugs can help people with recurrent ovarian cancer.
Interventions
- DRUG Carboplatin
- DRUG Triciribine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-09 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01690468
The ClinicalTrials.gov registry entry for NCT01690468 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prescient Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT01690468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01690468 about?
NCT01690468 is a clinical study titled "PTX-200 and Carboplatin in Ovarian Cancer". The main purpose of this study is to determine if Triciribine (TCN) and carboplatin are safe and tolerable when given together, and to determine if this combination of drugs can help people with recurrent ovarian cancer.
What is the current status of trial NCT01690468?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-09. Estimated completion is 2019-12.
What interventions are being tested in trial NCT01690468?
The interventions under investigation include: Carboplatin (DRUG), Triciribine (DRUG).
Who is sponsoring clinical trial NCT01690468?
This trial is sponsored by Prescient Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.